Markets:

Overview

News

Currencies

International

Treasuries

Fate Therapeutics, Inc. - Common Stock (NQ:FATE)

1.545 +0.295 (+23.60%)

Streaming Delayed Price Updated: 2:45 PM EDT, May 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Fate Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

A Preview Of Fate Therapeutics's Earnings ↗

February 23, 2024

Via Benzinga

Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results

February 15, 2024

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

February 02, 2024

From Fate Therapeutics, Inc.

Via GlobeNewswire

Analyst Ratings for Fate Therapeutics ↗

November 09, 2023

Via Benzinga

Recap: Fate Therapeutics Q3 Earnings ↗

November 08, 2023

Via Benzinga

Fate Therapeutics Inc. (NASDAQ: FATE) Near the Top of Equities by Percentage Gain on 9/18

September 18, 2023

Via Investor Brand Network

Analyst Ratings for Fate Therapeutics ↗

September 07, 2023

Via Benzinga

Billionaire Steve Cohen Is Betting Big on Fate Therapeutics (FATE) Stock ↗

January 29, 2024

Billionaire Steve Cohen is taking a massive stake in this little-known biotech company, leading FATE stock to surge more than 17%.

Via InvestorPlace

Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors

January 08, 2024

From Fate Therapeutics, Inc.

Via GlobeNewswire

Pinstripes, SoFi Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

January 03, 2024

U.S. stock futures were lower this morning, with the Dow Jones futures falling around 60 points on Wednesday. Shares of Pinstripes (NYSE: PNST) shares fell in pre-market trading after surging 22% on...

Via Benzinga

Topics Stocks

Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 13, 2023

From Fate Therapeutics, Inc.

Via GlobeNewswire

The Latest Analyst Ratings for Fate Therapeutics ↗

August 16, 2023

Via Benzinga

Where Fate Therapeutics Stands With Analysts ↗

May 05, 2023

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

December 12, 2023

Via Benzinga

Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

November 08, 2023

From Fate Therapeutics, Inc.

Via GlobeNewswire

FATE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

November 03, 2023

From Bragar Eagel & Squire

Via GlobeNewswire

Fate Therapeutics: Q1 Earnings Insights ↗

May 03, 2023

Via Benzinga

Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results

October 25, 2023

From Fate Therapeutics, Inc.

Via GlobeNewswire

Fate Therapeutics to Present at Upcoming September Investor Conferences

August 31, 2023

From Fate Therapeutics, Inc.

Via GlobeNewswire

FATE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

August 27, 2023

From Bragar Eagel & Squire

Via GlobeNewswire

Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates

August 08, 2023

From Fate Therapeutics, Inc.

Via GlobeNewswire

Stocks That Hit 52-Week Lows On Tuesday ↗

August 01, 2023

On Tuesday, 46 stocks hit new 52-week lows.

Via Benzinga

Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results

July 28, 2023

From Fate Therapeutics, Inc.

Via GlobeNewswire

FATE THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Fate Therapeutics, Inc. - FATE

June 30, 2023

From Kahn Swick & Foti, LLC

Via Business Wire

FATE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

June 21, 2023

From Bragar Eagel & Squire, P.C.

Via Business Wire

Why Shares of Fate Therapeutics Soared This Week ↗

June 16, 2023

The company's shares bounced back after a stock sale last week.

Via The Motley Fool

Fate ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

June 08, 2023

From Bragar Eagel & Squire, P.C.

Via Business Wire

FATE THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Fate Therapeutics, Inc. - FATE

June 05, 2023

From Kahn Swick & Foti, LLC

Via Business Wire

Fate Therapeutics to Present at Upcoming June Investor Conferences

May 31, 2023

From Fate Therapeutics, Inc.

Via GlobeNewswire

NASDAQ:FATE Long Term Investor Alert: Investigation of Potential Wrongdoing at Fate Therapeutics, Inc. ↗

May 24, 2023

San Diego, CA -- (SBWIRE) -- 05/24/2023 -- An investigation was announced for investors in shares of Fate Therapeutics, Inc. (NASDAQ:FATE) concerning potential breaches of fiduciary duties by certain...

Via SBWire

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.